Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESK-001 in renal impairment
NCT06962774Phase 1Completed
- Sponsor
- Alumis Inc.
- Start
- Apr 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of envudeucitinib (4 arms), sponsored by Alumis Inc. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Area Under the Plasma Concentration-Time Curve from Time Zero to the Time of the Last Quantifiable Concentration at 48 hours and 2 more. Started Apr 2025; status: completed.
02
Drugs
envudeucitinib
Beyond the preview
Go deeper on NCT06962774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06962774.